Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 2.2 chemically synthesized semaglutide injection, intended for the treatment of type 2 diabetes. Semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, has been approved in China for the treatment of type 2 diabetes since 2021 and for weight reduction in 2024. Notably, this marks the first time a chemically synthesized version of semaglutide has been granted approval for clinical trials in the country.
The approval underscores Humanwell’s commitment to advancing novel therapeutic options for patients with type 2 diabetes and potentially expanding access to a widely recognized GLP-1 agonist. The clinical trial is expected to evaluate the safety, tolerability, and efficacy of the chemically synthesized semaglutide injection, potentially offering a new treatment option in the diabetes management landscape.- Flcube.com
